Literature DB >> 17428354

A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3.

B Hellmich1, E Csernok, G Fredenhagen, W L Gross.   

Abstract

OBJECTIVE: Conventional direct enzyme-linked immunosorbent assays (ELISA) for the detection of anti-neutrophil cytoplasm antibodies (ANCA) often lack sensitivity because epitopes of the target antigen are hidden by binding to the ELISA plate. This study was designed to evaluate a novel ELISA method for detection of ANCA against proteinase-3 (PR3) for the diagnosis of Wegener's granulomatosis (WG) using PR3 presented in its native form.
METHODS: Sera from four subgroups of patients with a diagnosis of WG (n=86), 80 healthy controls and 450 disease controls were tested for the presence of C-ANCA/PR3-ANCA by anchor ELISA, direct ELISA, capture ELISA, indirect immunofluorescence (IFT) and immunoblotting.
RESULTS: In prospectively analysed consecutive patients, anchor ELISA showed the highest sensitivity for a diagnosis of WG of 96.0% (95% CI: 79.6-99.3), followed by IFT 92.0% (73.9-98.8), capture ELISA 72.0 (50.6-87.9) and direct ELISA 60.0 (38.7-78.8). Specificity was high for all methods and ranged from 98.5 (97.0-99.4) to 95.5% (97.9-99.8). Receiver operating characteristics curve analysis revealed that the overall diagnostic performance of the anchor ELISA was significantly superior compared to the direct ELISA and the capture ELISA in patients with generalized WG, and also compared to IFT and immunoblotting in patients with localised WG.
CONCLUSION: Anchor ELISA is a novel highly sensitive and specific method for the detection of PR3-ANCA in patients with WG, which may replace the need for a combined analysis with IFT and ELISA in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17428354

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

Review 1.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

Review 2.  Wegener's granulomatosis: the current view.

Authors:  Frank Moosig; Peter Lamprecht; Wolfgang L Gross
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 3.  Laboratory investigation in the diagnosis of vasculitis.

Authors:  Luis Felipe Flores-Suárez
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.592

Review 4.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

Review 5.  [Paradigm shift in ANCA diagnostics : New international consensus recommendations].

Authors:  E Csernok; N Kempiners; B Hellmich
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 6.  [Wegener's granulomatosis and microscopic polyangiitis].

Authors:  K de Groot; E Reinhold-Keller
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

7.  Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis.

Authors:  J D Finkielman; P A Merkel; D Schroeder; G S Hoffman; R Spiera; E W St Clair; J C Davis; W J McCune; A Lears; S R Ytterberg; A M Hummel; M A Viss; T Peikert; J H Stone; U Specks
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

Review 8.  Current and emerging techniques for ANCA detection in vasculitis.

Authors:  Elena Csernok; Frank Moosig
Journal:  Nat Rev Rheumatol       Date:  2014-06-03       Impact factor: 20.543

Review 9.  [Diagnostics of glomerulonephritis].

Authors:  S M Weiner; R Waldherr; J Kriegsmann
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

Review 10.  ANCA testing: the current stage and perspectives.

Authors:  Elena Csernok
Journal:  Clin Exp Nephrol       Date:  2012-11-23       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.